Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EVEKEO vs ADDERALL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
EVEKEO (sodium nitrite and sodium thiosulfate) is a cyanide antidote. Sodium nitrite induces methemoglobin formation, which binds free cyanide. Sodium thiosulfate provides a sulfur donor for conversion of cyanide to thiocyanate via rhodanese.
Adderall 15 is a combination of amphetamine and dextroamphetamine, which increase synaptic concentrations of norepinephrine and dopamine by inhibiting their reuptake and promoting their release from presynaptic terminals.
Treatment of acute cyanide poisoning,Off-label: Prevention of cyanide toxicity from sodium nitroprusside infusion
Attention deficit hyperactivity disorder (ADHD),Narcolepsy
5 mg IV infused over 1 hour every 2 weeks until disease progression or unacceptable toxicity. Reduce dose for adverse reactions.
10-20 mg orally once daily in the morning; may increase by 5-10 mg weekly; maximum 40 mg/day.
Terminal elimination half-life: 2-3 hours. Clinical context: Short half-life supports multiple daily dosing for seizure control. May be prolonged in hepatic impairment.
Mean terminal half-life: d-amphetamine 10 h, l-amphetamine 13 h (range 9-14 h); for ADDERALL 15 (3:1 mix), effective half-life ~11 h; clinical context: dosing interval typically QD-BID.
Sodium nitrite is metabolized primarily to methemoglobin and nitric oxide. Sodium thiosulfate is metabolized to thiocyanate by rhodanese.
Amphetamine is metabolized primarily by hepatic CYP2D6 and to a lesser extent by CYP2C19 and CYP2C9, with some minor pathways involving dopamine beta-hydroxylase.
Renal: 30-50% as unchanged drug; fecal: 50-70% as metabolites and unchanged drug.
Primarily renal (90% as unchanged drug and metabolites; ~30% unchanged, 40% as 4-hydroxyamphetamine and conjugates, 20% as other metabolites); minimal biliary/fecal elimination (<3%).
40-50% bound to serum albumin and α1-acid glycoprotein.
~16-20%; primarily binds to albumin, with minor binding to alpha-1-acid glycoprotein.
0.6-0.8 L/kg. Clinical meaning: Moderate distribution suggests limited tissue penetration; primarily confined to extracellular fluid.
Vd: 3.0-4.5 L/kg (range 2.6-5.6); indicates extensive tissue distribution, including brain, with accumulation in kidneys and liver.
Oral: 85-95%. Rectal: 70-80%. Intramuscular: 90-100%.
Oral: ~76% (range 64-95%) for mixed amphetamine salts; bioavailability reduced by acidic gastric p H and increased with food (Tmax delayed but AUC unchanged).
No adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) due to limited data.
GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: contraindicated.
No adjustment required for mild hepatic impairment (Child-Pugh A). Not recommended for moderate or severe hepatic impairment (Child-Pugh B or C) due to limited data.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Not approved for pediatric patients; safety and efficacy not established.
Weight-based: <50 kg: 2.5-5 mg once daily; 50-100 kg: 5-10 mg once daily; >100 kg: adult dosing.
No specific dose adjustment recommended; clinical studies included patients ≥65 years with no overall differences in safety or efficacy.
Start at 2.5-5 mg once daily; increase slowly due to increased sensitivity and cardiovascular risk.
Risk of severe hypotension and methemoglobinemia. Monitor methemoglobin levels. Use caution in patients with low oxygen saturation.
WARNING: ABUSE AND DEPENDENCE. CNS stimulants, including Adderall, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence throughout therapy.
Can cause severe hypotension requiring vasopressors,Methemoglobinemia may reduce oxygen delivery; avoid in patients with significant anemia or G6PD deficiency,Thiocyanate accumulation with prolonged use, especially in renal impairment
Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities or other serious heart problems,Blood pressure and heart rate increases,Psychiatric adverse events (exacerbation of pre-existing psychosis, manic episodes, aggressive behavior),Seizures (may lower seizure threshold),Peripheral vasculopathy including Raynaud's phenomenon,Serotonin syndrome risk, especially with concomitant serotonergic drugs,Long-term growth suppression in children
Hypersensitivity to sodium nitrite or sodium thiosulfate,Methemoglobin reductase deficiency
Hypersensitivity to amphetamine or other components,Concurrent use or within 14 days of MAOIs (risk of hypertensive crisis),Glaucoma,Hyperthyroidism,Agitated states,History of drug abuse,Cardiovascular disease (symptomatic, moderate to severe hypertension, advanced arteriosclerosis, structural cardiac abnormalities)
No known food interactions. EVEKEO is administered intravenously and is not affected by oral intake. However, in neonates, careful monitoring of electrolyte and fluid balance is important.
Avoid high-fat meals close to dosing as they may delay absorption. Acidic foods (e.g., citrus, cola, vitamin C) can decrease absorption; take with non-acidic fluids. Avoid alcohol and caffeine-containing products.
Pregnancy Category N (not assigned). No adequate human data; based on animal studies, fetal harm is possible. Avoid use in first trimester if alternative available. Risk in second and third trimesters unknown.
First trimester: Possible increased risk of congenital malformations (cardiac, oral clefts) based on limited human data; animal studies show dose-dependent teratogenicity. Second/third trimesters: Risk of fetal growth restriction, preterm delivery, neonatal withdrawal (irritability, feeding problems), and persistent pulmonary hypertension.
No data on excretion in human milk. M/P ratio unknown. Caution if breastfeeding; consider risk vs benefit.
Present in breast milk; M/P ratio approximately 2.5-7.5. Potential for infant stimulation, insomnia, reduced weight gain. Caution recommended; consider delaying breastfeeding until 1-2 hours after dose.
No pharmacokinetic studies in pregnancy; dose adjustment recommendations not established. Use lowest effective dose and shortest duration.
Pregnancy reduces amphetamine plasma concentrations by 15-50% during second/third trimesters due to increased clearance. Dose may need upward titration to maintain clinical effect, with careful monitoring for adverse effects.
EVEKEO is a beta-adrenergic agonist indicated for the treatment of bradycardia in premature neonates. It is given intravenously and has a rapid onset of action (1-2 minutes). Monitor heart rate and blood pressure continuously during infusion. Use with caution in patients with hyperthyroidism, diabetes, or history of seizures. Tachyphylaxis may develop with prolonged use.
Adderall 15 mg (amphetamine/dextroamphetamine) is an immediate-release formulation; onset 30-60 min, duration 4-6 hours. Avoid afternoon doses to prevent insomnia. Monitor for hypertension, tachycardia, and growth suppression in children. Consider drug holidays to assess need and reduce tolerance. Do not use with MAOIs or within 14 days of MAOI therapy. Risk of abuse and dependence; screen for substance use history. Use with caution in patients with pre-existing cardiovascular disease or psychiatric disorders.
This medication is for hospital use only and will be given by a healthcare professional.,It is used to increase your baby's heart rate and improve blood flow.,The dose may be adjusted based on your baby's response and heart rate.,Potential side effects include increased heart rate, high blood pressure, or arrhythmias.,Report any signs of allergic reaction, such as rash or difficulty breathing, immediately.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Take the first dose in the morning; if prescribed a second dose, take it by early afternoon to avoid sleep problems.,Swallow tablet whole; do not crush or chew.,Avoid alcohol and caffeine; may increase side effects like nervousness and rapid heartbeat.,Report chest pain, palpitations, shortness of breath, or fainting immediately.,Inform your doctor of all medications, including over-the-counter and herbal products, especially antidepressants.,May cause weight loss; monitor growth in children.,Can impair ability to drive or operate machinery until you know how it affects you.,Store at room temperature away from moisture and heat.,Do not abruptly stop; taper under medical supervision to avoid withdrawal.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EVEKEO vs ADDERALL 15, answered by our medical review team.
EVEKEO is a CNS Stimulant that works by EVEKEO (sodium nitrite and sodium thiosulfate) is a cyanide antidote. Sodium nitrite induces methemoglobin formation, which binds free cyanide. Sodium thiosulfate provides a sulfur donor for conversion of cyanide to thiocyanate via rhodanese.. ADDERALL 15 is a CNS Stimulant that works by Adderall 15 is a combination of amphetamine and dextroamphetamine, which increase synaptic concentrations of norepinephrine and dopamine by inhibiting their reuptake and promoting their release from presynaptic terminals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EVEKEO and ADDERALL 15 depend on the specific clinical indication. These are both CNS Stimulant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EVEKEO is: 5 mg IV infused over 1 hour every 2 weeks until disease progression or unacceptable toxicity. Reduce dose for adverse reactions.. The standard adult dose of ADDERALL 15 is: 10-20 mg orally once daily in the morning; may increase by 5-10 mg weekly; maximum 40 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EVEKEO and ADDERALL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EVEKEO is classified as Category C. Pregnancy Category N (not assigned). No adequate human data; based on animal studies, fetal harm is possible. Avoid use in first trimester if alternative available. Risk in second . ADDERALL 15 is classified as Category C. First trimester: Possible increased risk of congenital malformations (cardiac, oral clefts) based on limited human data; animal studies show dose-dependent teratogenicity. Second/t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.